SUBSCRIBE
SUBSCRIBE
News   Drug Development

US FDA Says No New Warnings on Biogen Idec, Inc. (Massachusetts) (JOBS), Elan Corporation PLC (JOBS) MS Drug

September 17, 2009 | 
1 min read

Bookmark and Share

Reuters -- A Biogen Idec and Elan Corp multiple sclerosis drug does not need new warnings despite additional reports of a life-threatening brain infection, U.S. regulators said on Wednesday.

Clinical research Postmarket research
Food and Drug Administration (FDA) Biogen
MORE ON THIS TOPIC
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Weight loss
Kallyope Discreetly Drops Disappointing Data for Oral Obesity Candidate
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Gothenburg, Sweden – April 17, 2020: AstraZeneca in Gothenburg is one of three strategic global R&D centres in medicine. A big sign with the company logotype just outside the entrance.
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
February 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky